Loading clinical trials...
Loading clinical trials...
A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer
Conditions
Interventions
Bardoxolone methyl
Bardoxolone methyl
+8 more
Locations
5
United States
Rocky Mountain Cancer Center (US Oncology)
Denver, Colorado, United States
Cancer Centers of Florida (US Oncology)
Ocoee, Florida, United States
Central Indiana Cancer Centers (US Oncology)
Indianapolis, Indiana, United States
Sammons Cancer Center (US Oncology)
Dallas, Texas, United States
Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology)
Vancouver, Washington, United States
Start Date
September 30, 2007
Primary Completion Date
November 1, 2009
Completion Date
November 1, 2009
Last Updated
May 29, 2025
NCT02600949
NCT03050268
NCT06423326
NCT07542041
NCT07283705
NCT07438106
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions